LINCOLN PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of LINCOLN PHARMACEUTICALS have increased by 11.30% YoY .
The Earnings Per Share (EPS) of LINCOLN PHARMACEUTICALS has increased by 5.11 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
LINCOLN PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 531633|NSE : LINCOLN]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹472 Cr | ₹424 Cr | ₹386 Cr | ₹366 Cr | ₹36,061,429 Cr |
| Expenses | ₹377 Cr | ₹337 Cr | ₹321 Cr | ₹299 Cr | ₹30,829,810 Cr |
| Operating Profit (Excl OI) | ₹95 Cr | ₹87 Cr | ₹66 Cr | ₹67 Cr | ₹5,231,619 Cr |
| Other Income | ₹10.00 Cr | ₹5.66 Cr | ₹11 Cr | ₹5.64 Cr | ₹545,372 Cr |
| Interest | ₹1.45 Cr | ₹1.56 Cr | ₹2.02 Cr | ₹4.00 Cr | ₹541,101 Cr |
| Depreciation | ₹8.09 Cr | ₹7.56 Cr | ₹7.33 Cr | ₹6.68 Cr | ₹611,181 Cr |
| Profit Before Tax | ₹96 Cr | ₹84 Cr | ₹67 Cr | ₹62 Cr | ₹4,624,710 Cr |
| Profit After Tax | ₹69 Cr | ₹62 Cr | ₹51 Cr | ₹49 Cr | ₹3,464,941 Cr |
| Consolidated Net Profit | ₹69 Cr | ₹62 Cr | ₹51 Cr | ₹49 Cr | ₹3,462,296 Cr |
| Earnings Per Share (Rs) | ₹36.40 | ₹34.63 | ₹31.08 | ₹25.72 | ₹24.36 |
| PAT Margin (%) | 13.68 | 13.97 | 14.19 | 12.88 | 12.92 |
| ROE(%) | 15.59 | 17.35 | 18.32 | 17.67 | 19.75 |
| ROCE(%) | 21.82 | 24.29 | 24.90 | 22.30 | 22.50 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.02 | 0.12 |
Key Financials |
||
| Market Cap | : | ₹ 1,195.4 Cr |
| Revenue (TTM) | : | ₹ 550.5 Cr |
| Net Profit(TTM) | : | ₹ 87.3 Cr |
| EPS (TTM) | : | ₹ 43.6 |
| P/E (TTM) | : | 13.7 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| LINCOLN PHARMACEUTICALS | 0.8% | -0.6% | 51.1% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -6.5% | 55.3% |
| CIPLA | 4.1% | -4.8% | 55.6% |
| DR REDDYS LABORATORIES | 4% | 0.8% | 29.4% |
| ZYDUS LIFESCIENCES | -1.2% | -5.2% | 83.9% |
| DIVIS LABORATORIES | 7.8% | 17.4% | 20.3% |
| MANKIND PHARMA | 1.3% | 7% | NA |
| TORRENT PHARMACEUTICALS | 3.9% | 5.1% | 66.1% |
| LUPIN | 0.6% | 0.5% | 127.2% |
LINCOLN PHARMACEUTICALS Revenues
[BOM: 531633|NSE : LINCOLN]
| Y-o-Y | 11.30 % |
| 5 Yr CAGR | -93.98 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹472 Cr | 11.30 | |
| Mar2022 | ₹424 Cr | 9.75 | |
| Mar2021 | ₹386 Cr | 5.56 | |
| Mar2020 | ₹366 Cr | -100.00 | |
| Mar2019 | ₹36,061,429 Cr | - | |
LINCOLN PHARMACEUTICALS Operating Profit
[BOM: 531633|NSE : LINCOLN]
| Y-o-Y | 9.52 % |
| 5 Yr CAGR | -93.46 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹95 Cr | 9.52 | |
| Mar2022 | ₹87 Cr | 33.02 | |
| Mar2021 | ₹66 Cr | -2.53 | |
| Mar2020 | ₹67 Cr | -100.00 | |
| Mar2019 | ₹5,231,619 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -1.61 % |
| 5 Yr CAGR | 8.65 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 20.22% | -1.61 | |
| Mar2022 | 20.55% | 21.17 | |
| Mar2021 | 16.96% | -7.63 | |
| Mar2020 | 18.36% | 26.53 | |
| Mar2019 | 14.51% | - | |
LINCOLN PHARMACEUTICALS Profit After Tax
[BOM: 531633|NSE : LINCOLN]
| Y-o-Y | 11.41 % |
| 5 Yr CAGR | -93.31 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹69 Cr | 11.41 | |
| Mar2022 | ₹62 Cr | 21.02 | |
| Mar2021 | ₹51 Cr | 5.60 | |
| Mar2020 | ₹49 Cr | -100.00 | |
| Mar2019 | ₹3,462,296 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -2.08 % |
| 5 Yr CAGR | 1.44 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 13.68 % | -2.08 | |
| Mar2022 | 13.97 % | -1.55 | |
| Mar2021 | 14.19 % | 10.17 | |
| Mar2020 | 12.88 % | -0.31 | |
| Mar2019 | 12.92 % | - | |
LINCOLN PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 531633|NSE : LINCOLN]
| Y-o-Y | 5.11 % |
| 5 Yr CAGR | 10.56 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹36 | 5.11 | |
| Mar2022 | ₹35 | 11.42 | |
| Mar2021 | ₹31 | 20.84 | |
| Mar2020 | ₹26 | 5.58 | |
| Mar2019 | ₹24 | - | |
LINCOLN PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 531633|NSE : LINCOLN]
| Y-o-Y | -10.17 % |
| 5 Yr CAGR | -0.76 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 21.82% | -10.17 | |
| Mar2022 | 24.29% | -2.45 | |
| Mar2021 | 24.9% | 11.66 | |
| Mar2020 | 22.3% | -0.89 | |
| Mar2019 | 22.5% | - | |
LINCOLN PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹597.7 |
| Current MarketCap | : | ₹ 1,195.4 Cr |
| Updated EOD on | : | Apr 26,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LINCOLN PHARMACEUTICALS | 0.8% |
-0.6% |
51.1% |
| SENSEX | 0.9% |
1.5% |
23.6% |
LINCOLN PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE MIDSMALLCAP | 4% | 9.7% | 67.3% |
| S&P BSE SMALL CAP | 4% | 11.6% | 67.3% |
| S&P BSE HEALTHCARE | 3% | 4% | 55.2% |
| S&P BSE ALLCAP | 2.3% | 5% | 41.4% |
No NSE index found
You may also like the below Video Courses
FAQ about LINCOLN PHARMACEUTICALS Financials
How the annual revenues of LINCOLN PHARMACEUTICALS have changed ?
The Revenues of LINCOLN PHARMACEUTICALS have increased by 11.30% YoY .
How the Earnings per Share (EPS) of LINCOLN PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of LINCOLN PHARMACEUTICALS has increased by 5.11 % YoY .
Check out Intrinsic Value of Peers of LINCOLN PHARMACEUTICALS
Compare Stock Analytics of Peers of LINCOLN PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
